Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors

American Journal of Surgical Pathology

Volumn 23, Issue 3, 1999, Pages 323-328

  Caduff, Rosmarie F ^a   Svoboda Newman, Suzette M ^a   Ferguson, Amy W ^a   Johnston, Carolyn M ^a   Frank, Thomas S ^a,b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b Myriad Genetics Laboratories Inc   (United States)

Author keywords

Borderline; Carcinoma; Ki RAS; Ovarian neoplasms; P53

Indexed keywords

PROTEIN P53;

ARTICLE; FEMALE; GENE MUTATION; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; ONCOGENE K RAS; OVARY CANCER; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA, MUCINOUS; CARCINOMA, PAPILLARY; CODON; FEMALE; GENES, P53; GENES, RAS; HUMANS; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 0033055861     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-199903000-00012     Document Type: Article

References (34)

1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
2. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98: 81-7.
3. Caduff RF, Johnston CM, Frank TS. Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 1995;146: 182-8.
4. Colsian TJ, Norris HJ. Ovarian epithelial tumors of low malignant potential: a review. Int J Gynecol Pathol 1983;1:367-82.
5. Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res 1992;52: 1974-80.
6. de Nictolis M, Montironi R, Tommasoni S, et al. Benign, borderline, and well-differentiated malignant intestinal mucinous tumors of the ovary: a clinicopathologic, histochemical, immunohistochemical, and nuclear quantitative study of 57 cases. Int J Gynecol Pathol 1994;13:10-21.
7. Easton DF, Ford D, Bishop DT, Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995;56:265-71.
8. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
9. Frank TS, Bartos RE, Haefner HK, Roberts JK, Wilson MD. Hubbell GP. Loss of heterozygosity and overexpression of the p53 gene in ovarian carcinoma. Mod Pathol 1994;7:3-8.
10. Frank TS, Svoboda-Newman SM, Hsi ED. Comparison of methods for extracting DNA from formalin fixed paraffin sections for non-isotopic PCR. Diagn Mol Pathol 1996;5:220-4.
11. Fujita M, Enomoto T, Inoue M, et al. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 1994;85: 1247-56.
12. Hart WR, Morris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer 1973; 31:1031-45.
13. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumors in the female pelvis. Am J Surg Pathol 1978;2:339-55.
14. International Federation of Gynecology and Obstetrics. FIGO stages - 1988 revision. Gynecol Oncol 1989;35:125-7.
15. Kerns BJ, Jordan PA, Moore MH, et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem 1992;40:1047-51.
16. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol 1995;26:387-92.
17. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD. p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 1994;102:671-6.
18. Kurman RJ, Trimble CL. The behavior of serous tumors of low malignant potential: are they ever malignant? Int J Gynecol Pathol 1993;12:120-7.
19. Lee JH, Kang YS, Park SY, et al. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet 1995;85:43-50.
20. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
21. Lin S-Y, Chen P-H, Wang CK, et al. Mutation analysis of K-ras oncogenes in gastroenterologic cancers by the amplified created restriction sites method. Am J Clin Pathol 1993;100:656-89.
22. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51: 2979-84.
23. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 1993;53:1489-92.
24. Prioleau J, Schnitt SJ. p53 antigen loss in stored paraffin slides [letter]. N Engl J Med 1995;332:1521-2.
25. Risinger JI, Dent GA, Ignar Trowbridge D, et al. p53 gene mutations in human endometrial carcinoma. Mol Carcinog 1992;5: 250-3.
26. Russell P. Borderline epithelial tumours of the ovary: a conceptual dilemma. Clin Obstet Gynecol 1984;11:259-77.
27. Rutgers JL, Scully RE. Ovarian mulleriun mucinous papillary cystadenomas of borderline malignancy: a clinicopathologic analysis. Cancer 1988;61:340-8.
28. Rutgers JL, Scully RE. Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy of mullerian type: a clinicopathologic analysis. Cancer 1988;64:546-54.
29. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Rosai J, Sobin LH (eds): Atlas of Tumor Pathology. Washington, D.C.: Armed Forces Institute of Pathology; 1998:51-140.
30. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Rosai J, Sobin LH (eds): Atlas of Tumor Pathology. Washington, D.C.: Armed Forces Institute of Pathology; 1998:28-31.
31. Teneriello MG, Ebinba M, Linnoila RI, et al. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993;53: 3103-8.
32. van Haaften-Day C, Russell P, Boyer CM, et al. Expression of cell regulatory proteins in ovarian borderline tumors. Cancer 1996;77: 2092-8.
33. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319: 525-32.
34. Wertheim I, Muto MG, Welch WR, Bell DA, Berkowitz RS, Mok SC. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst 1994;86:1549-51.